In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts.
In Intellectual Asset Management (IAM), Fresenius Kabi Intellectual Property Chief Rachel Moodie discusses the worsening problem of patent thickets in the U.S. biosimilars market. Featured in the article is MGA’s report on patent thickets, as well as a quote from MGA’s Christy Robinson, who voiced her concern regarding the future of the biosimilars market.
The Center for Biosimilars has announced that MGA’s recent report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was the top-read article on its website for the week of June 14, 2021.
On Thursday, The Center for Biosimilars, a sister site of The American Journal of Managed Care, published an article discussing the differences between the patent systems in the United States and Europe when it comes to biosimilars. The article featured the latest report released by MGA, and authored by Alex Brill and Christy Robinson, titled “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing”:
In his Forbes article, Personal Finance Contributor Ted Knutson discussed Tuesday’s Senate Committee on Finance hearing that focused on climate change tax reform. During the hearing, leaders on both sides of the aisle asserted that new clean energy laws should be technology neutral, so that no one industry “wins.”
On fee.org, the website for the Foundation for Economic Education, author Brad Polumbo reported on Alex Brill’s estimates of the true cost of the American Rescue Plan.
